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ABSTRACT : In the experiment of a donor lung with a three hour warm ischemia
the　 effects　 of　 antioxidant　 drugs,　 CV-3611　 and　 α-tocopherol,　 on　 reperfusion　 injury　 were
evaluated on dogs with left lung transplantation.
1)CV-3611　 and　 α-tocopherol　 are　 of　 great　 benefit　 to　 prevent　 a　donor　 lung　 from　 reperfusion
injury, remaining satisfactory alveolar ventilation.
2)The　 addition　 of　CV-3611　 and　 α-tocopherol　 was　 depressed　 enough　 to　generate　 the　 volume
of lipid peroxidase in the lung tissues. 
3) The pulmonary vascular resistance increased without exception in all groups, 
demonstrating no effect of antioxidant drugs.
4)The　 statistic　 compliance　 was　 remained　 satisfactory　 by　 α-tocopherol.
5) There was a tendency toward a decrease in oxidative product in neutrophils by CV-3611.
This　 results　 suggest　 that　 CV-3611　 and　 α-tocopherol　 should　 be　 of　 great　 use　 to　 avoid
occurring reperfusion injury to ischemic lungs.
       INTRODUCTION 
 Great concern regarding the probloms to solve 
in a lung graft immediately after lung trans-
plantation is to minimize reperfusion injury, 
which corresponds to acute lung edema. In 1985 
McCord corroborated the concept of tissue 
injury caused by free radical at the time of reper-
fusion for ischemic myocardium and intestine 
and it is reported that the main cause of tissue 
injury is superoxide which generates from the 
ground substance of xanthine and hypoxantine 
(Fig. 1). 
 Recent study clarified that one of the cause 
of reperfusion lung injury is peroxidation pro-
duct generated by granulocytes" ". 
 This study aimed at improvement of a result 
of organ transplantation by making use of
protective effects of a-tocopherol and CV-3611, 
derivates of vitamin C, to ischemic preserved 
lung.
Fig. 1. Proposed Mechanism for Ischemia-Induced 
      Production of Superoxide.
   MATERIALS AND METHODS 
1) Experimental animal 
 Mongrel dogs weighing from 8 to 13kg were 
used in this study. These dogs were supplied 
from the Animal Center of Nagasaki University 
School of Medicine. 
2) Method 
 Mongrel dogs were anesthetized and main-
tained on sodium pentobarbital, intubated with 
a cuffed endotracheal tube and ventilated with 
100% oxygen using a volume respirator (Harvard). 
The tidal volume set up to were 30m1/kg, respi-
ratory rate 12-14/min. A 5F Swan-Ganz catheter 
was inserted from the external jugular vein. 
 Thoracotomy was made at the 5th ICS on the 
left side and hilar stripping was performed by 
mobilizing the bronchus, pulmonary artery and 
vein and also dividing the bronchial artery, lym-
phatic channel and vagal nerve branches. 
 After administering heparin 200U/kg intrave-
nously, left pulmonary function was evaluat-
ed by temporary blocking test of the right 
bronchus and pulmonary artery. 
 Cardiac output and the pressure of the 
pulmonary artery were measured and static lung 
compliance was calculated by airway pressure-
volume curve. 
 Warm ischemic preservation for three hours 
was continued on the condition of 60 to 80% 
inflated state by room air and dogs were divided 
into the three groups. 
Group 1 : simple warm ischemia (N=6). 
Group 2 : CV-3611 20mg/kg per os administra-
tion one hour prior to induction of anesthesia 
(N = 7). 
Group 3: a-tocopherol 20mg/kg iv administra-
tion immediately after thoracotomy (N=7). 
Unilateral occulusion tests of right pulmonary 
artery and bronchus by the same way as made 
prior to ischemia were repeated at 10, 60, 90 and 
120 min following reperfusion. 
 At the same time, generation of superoxide 
in granulocytes of the pulmonary vein and lipid 
peroxide in serum and lung tissues were me-
asured. Histologic examination of lung tissue 
was made by H-E staining 120 min after re-
perfusion. 
1) Measurement of lipid peroxide in blood and
lung tissue 
 Fluoroscence method was used for measuri-
ng lipid peroxide as reported by Yagi4' and the 
values were corrected by containing protein 
volume. 
(1) Serum 
 Two ml of heparinized blood were centrifuged 
at 3000rpm for 10min, added 4ml of 1/12N H2SO4 
and 0.5m1 of 10% phospho-tungstic acid at room 
temperature for 5 min, centrifuged at 3000rpm 
for 10 min. Added 2ml of 1/12N H2SO4 and 0.3m1 
of 10% phospho-tungstic acid centrifuged at 
3000rpm for 10 min, added 4m1 of distilled water 
and added lml of TBA reagent, heated at 95°C 
for 60 min, cooled at ice water bath, and vibrat-
ed with 5ml of n-butylalcohol, centrifuged at 
3000rpm for 10min and measured by excitation 
spectrum (515nm) with 553nm fluorescence. 
2) lung tissue 
 After taking a piece of lung tissue, it was 
stored in -160CC liguid nitrogen, adding nine 
times volume of water and adjusted to 10% 
homogenized liquing and 0.2m1 8.1% sodium 
dodecyl sulfate was mixed with 1.5ml of 20% 
acetic acid buffer (pH3.5), 1.5m1 of 0.8% TBA-
reagent and 0.6m1 of distilled water, heated at 
95°C for 60 min, cooled at ice-bath and mixed 
lml of distilled water with 15: 1 admixure of 
n-butyl alcohol and pyridine, centrifuged at 
3000rpm for 10 min, and measured by butyl 
alcohol layer by excitation spectrum (515nm) 
with 553nm fluorescence. 
(3) Protein measurement 
 Serum was diluted 500 times with distilled 
water, finally homogenized liquor of lung tissues 
was diluted 1000 times. Three ml of Lowry C 
solutions' was added to 0.6m1 of homogenized 
liquor of serum and lung tissue, incubated at 
25°C for 10 min, added 0.3m1 of 50% phenol 
solution and incubatd at 25'C for 30min, and 
made spectrophotometric measurement with 
750nni and calculated as the following equation 
serum : TBA=f/F X 0.5 X 1/0.02 nmol/ml 
correction by protein 
TBA=f/F X 0.5 X 1/0.02 = Y(500/1000) nmol/ 
mg protein 
f : fluorescence of sample 
F : fluorescence of standard 
Y : 500 times diluted protein 
lung tissue: TBA=f/F X 1/0.2 nmol/ml
correction by protein 
TBA=f/F X 1/0.2 = Y(100/1000) nmol/mg protein 
Lipid peroxidase value of serum immediately 
before reperfusion was regarded as 1 and that 
of lung tissue was used as the measured ualue. 
2) Measurement of oxidative product by neu-
trophils 
 Oxidative product by neutrophils was meas-
ured according to Flowcytometry method by 
Bass' and modified by Taniguchi7'. 
 0.lml of heparinized blood was added 1.9m1 
of 5,uM 2', 7'-dichlorofluorescin diacetate (DCFHDA) 
and 0.5m1 of EDTA which was adjusted to 24mM 
with PBS to avoid agglutinating neutrophils and 
added 10,ul of phorbol myristate acetate (PMA), 
incubated at 37CC for 25min, washed and cen-
trifuged at 1300rpm for 10min, treated with 0.87% 
NH4C1 lysing solution, rewashed with PBS and 
centrifuged at 1300rpm for 10min, suspended 
pellet with Hanks' solution and measured with 
Spectrum III (Ortho Co.). 
 B-start regarded the resting state in peripheral 
blood of dogs as 2-3% was set as negative control 
and B% regarded as generation capacity after 
PHA stimulation. 
 Figure 3 showed cytogram, indicating sizes of 
cells in foward light scatter of abscissa and 






 Figure 4a showed a histogram by SPIII at 
resting state and Figure 4b also showed a 
histogram at PHA stimulaton, indicating a for-
mal distribution of neutrophils by stimula-
tion. 
 The results were compared as an indicator 
of generation capacity of oxydative product (B% 
X Bmch) with the control value (1) immediately 
before reperfusion. 
3) Intrapulmonary shunt ratio 
Intrapulmonary shunt ratio was calculatd by 
simplified equation by Osaki". 
Qs/Qt=0.003 X AaDO2/4.5+AaD02 
PA02=1.0 X (760-47)-PaCO2 
AaDO2=713-PaCO2-PaO2 
4) Pulomonary vasucular resistance (PVR) 
PVR was calculated according to the following 
equation 80 X (PAP-LAP)/CO (dyne-sec/cm ') 
LAP : left atrial pressure 
CO: cardiac output 
5) static pulmonary compliance (ml/cmH2O) 
 The intratracheal pressure, flow speed, and 
tidal volume were simultaneously delineated on 
the graph, and the staitc pulmonary compliance 
was calculated by dividing tidal volume by 
intratreacheal pressure 1.4 sec after end-inpira-
tion, holding inspiration`". 
6) Pulmonary extravascular water (PEVW) 
PEVW was calculated accoriding to the fol-
lowing equation 
W-D/W 
W : wet lung weight 
weigh the lung after taking out 
D : dry lung weight 
weigh the lung after keeping at 110-120°C for 
48 hours 
 CV-3611 was supplied from Takeda Pharma. 
Co and a-tocopherol from Eizai Pharma. Co. 
Data were expressed as means±SD. 
 Statistical significance fo the data was es-
timated by Mann-Whitney U-test and P-values 
of less than 0.05 were considered to be sig-
nificant. 
          RESULT 
1) Pao2 (Fig. 5a) 
 Pa02 in Group 1 decreased in 271.6± 
111.5mmHg 10min after reperfusion in contrat 
to 429.5±79.6mmHg prior to reperfusion and
continued to a decrease. 
 In Group 3 Pa02 somewhat decreased al-
though those in Group 2 and 3 did not reduce 
afterwards. Pa02 60min later in Group 2 and 
3 (375.9±70.6 and 355.5±83.0) remained signifi-
cantly high (p<0.01) as compared with those in 
Group 1 (213.0±59.1) and an excellent oxygena-
tion was shown. 
(2) PaC02 (Fig. 5b). 
 In Group 1, PaC02 (38.5±9.3mmHg) was in-
creased 60min after reperfusion as compared 
with that (27.4±4.3) prior to reperfusion. 
Meanwhile those in Group 2 and 3 did not 
increase, showing a significant reduction (p< 
0.05)in Group 3 immediately after reperfusion 
and in Group 2 90 min after reperfusion. It was 
a reflection of satisfactory alveolar ventila-
tion. 
(3) Intrapulmonary shunt ratio (Fig. 6) 
 In Group 1, intrapulmonary shunt ratio was
Fig. 5a. Pa02
Fig. 5b. PaCO2
Fig. 6. Shunt rate
Fig. 8. Static lung compliance
Fig. 7. Pulmonary vascular resistence Fig. 9. Oxidative activity of neurophils
increased with time since 10 min after reperfu-
sion, showing 21.1±4.4 10 min after reperfusion 
and later indicating a continuous increase. On 
the other hand, those in Group 2 and 3 did not 
increase although that in Group 3 showed a 
slight increase. It was statistical significance 
(p<0.01) between Group 1 (23.5±2.0) and Group 
2, 3 (17.0±3.1, 17.9±3.7) 60 min after reperfu-
sion. 
(4) Pulmonary vascular resistence (Fig. 7) 
 PVR 10 min after reperfusion increased to 
2433±607 dyne.sec.cm-5 as compared with that 
(1409±239) prior to reperfusion in Group 1 and 
also it was a similar increase in Group 2 (from 
1245±518 to 2207±1041) and Group 3 (from 1282± 
389 to 2013±346). Thereafter, PVR remained 
high, showing a remarkable increase in Group 
1 as compared with those in Group 2 and 3. 
(5) Static lung compliance (Fig. 8) 
 Static lung compliance 120 min after re-
perfusion was reduced in all groups as com-
pared with prior to reperfusion, from 31.3± 
4.7m1/cmHZO to 21.9±3.7 in Group 1, from 29.2± 
3.7 to 25.6±6.1 in Group 2 and from 31.2±3.9 
to 27.0±3.0 in Gropup 3. Those in Group 3 
were significantly higher (p<0.05) than those in 
Group 1, showing a high tendency in Group 2. 
(6) Oxidative product by neutrophis in blood of 
the pulmonary vein (Fig. 9). 
 In Group 1, oxidative product increased with 
time, 1.03±0.06 times 10 min after, 1.18±0.25 
times 30 min after, 1.29±0.37 times 60min after 
and 1.39±0.32 times 120 min after reperfusion, 
as compared with that prior to reperfusion. In 
Group 3, it was almost the same tendency as 
1.09±0.17, 1.23±0.17, 1.23±0.33, 1.33±0.39, 
1.42±0.55. Meanwhile, in Group 2, it was de-
pressed without statistically significant differ-
ence. 
(7) Lipid peroxidase in blood of the pulmonary 
vein (Fig. 10). 
 In Group 1, lipid peroxidase content increas
Fig. 10. Lipid peroxidase in serum
Fig. 11. Lipid peroxidase in lung tissue
Fig. 12. Pulmonary extravascular water
ed with time, without statistical significance, 
1.062±0.095 10 min after, 1.123±0.198 60 min after 
and 1.197±0.139 120 min after reperfusion as 
compared that prior to reperfusion. There was 
no any variation between those in Group 2 and 
3 and no difference between Group 1 and 2 3. 
(8) Lipid peroxidase in lung tissues (Fig. 11) 
 Lipid perioxidase content in lung tissues 
120min after reperfusion showed 0.939±0.112 
nmol/mg protein in Group 1, 0.741±0.088 in 
Group 2 and 0.652±0.074 in Group 3. It was
a remarkable reduction (p<0.01) in Group 2 and 
3. 
(9) Pulmonary extravascular water (PEVW) 
 PEVW 120 min after reperfusion showed 
87.39±0.97% in Group 1, 86.53±1.61 in Group 2 
and 85.37±2.44 in Group 3. These were a slight 
decrease without significant difference in Group 
2 and 3 as compared with that in Group 1. 
(10) Histologic examination 
In Group 1, there was a significant finding of 
alveolar edema, destruction of alveolar structure 
and perivascular bleeding. On the other hand, 
in Group 2 and 3, alveolar atructure remained 
almost normal in spite of a presence of edema 
in the alveolar septum with the slight degree 
of perivascular bleeding.
         DISCUSSION 
 Many previous reports have shown that the 
maximum tolerable time duration of experi-
mental animals lies between 30 and 60 min in 
collapsed lungs at room temperature, two hours 
in ventilated lungs three hours in continuous 
inflated lungs10' 11). The major item of concern 
about lung storage is how to prevent a storag-
ed lung from reperfusion injury (RPI). Many 
research wark focus on the causes of reperfu-
sion injury which is provoked by activation 
of xanthine oxidase system and generation 
of hydroxylradical from activated neutor-
phils1' 1215' 
 Recently it is defined that human heart 
muscles do not contain XOD despite contain-
ing large amounts of XOD in the human lung 
tissues16'. The debate about generation of 
hydroxyl radical in XOD system are centered 
around the genesis that hypoxanthine originated 
from ATP during the ischemic phase reacts 
activated SOD, resulting in generation of 02-
via H2O2. On the consequence, .OH is generated 
and causes severe damage to the cells". The 
mechanisms of cell damage caused by neu-
trophils are complex. 
 Keith") reported that tissue damage is caused 
by a large amount of hydroxyl radical which 
is released by neutrophils activated by C5a and 
complement. The other hand, it is said that 
activated neutrophils release elastase which is 
consequent to inactivation of a1-antiprotease by
reacting with oxidative product". 
 Furthermore, oxidative product induces an 
inhibition of Ca` transport in the endoplasmic 
reticulum of muscles"'. As a result, Ca` makes 
phospholipase active and arachidonic acid cas-
cade reaction progressive which results in leu-
kotriens generation"'. 
 It is well known that LTB4 stimulates neu-
trophils and leukotoxin generation is acceler-
ated, forming a vicious circle of cell damage. 
Some researchers repoted that a ultra-long act-
ing HOCL is generated from myeloperoxidase 
originated from neutrophilsl9'. 
 It is acceptd that in all instances, oxidative 
product may trigger damage to tissue, therefore 
antioxidative drugs are necessary for avoiding 
and alleviating reperfusion injury syndrome. 
Meanwhile, it is well known that ascorbin aicd 
is capable for inactivation of 02-which generat-
ed in water-soluble fraction such as the cell 
membran and also acts as an excellent scav-
enger for • OH in the neutral status20' 21'. In 
contrast, in a presence of free metal of Fe 2' and 
Cu2+ and so on, ascorbin acid accelerate genera-
tion of oxidative product which is so-called 
prooxidant action. A drug of CV-3611 is fat-
soluble ascorbic acid, unlikely to be affected by 
free metal ion in cells and poseing only action 
antioxidant agents. 
 Many studies clarified that CV-3611 inhibits 
generation of lipid peroxidase in accordance 
with its concentration 2' and also prevent ische-
mic heart from reperfusion injury"). 
 At present, as the titers of CV-3611 are re-
duced by dissolution following oral admistra-
tion, so every effort has been made to minimize 
it in a very few reports. Hashimoto24' report-
ed that it continues to act during a six hours 
duraiton. In this series, 20mg/kg CV-3611 were 
orally administered 60 min before induciton of 
anesthesia since it takes six hours after 
reperfusion. There was a tendency toward re-
duction in generation of oxidative product of 
neutrophils until 90 min after reperfuison in ac-
cordance with Kuzuya' repor2' 3'. It is reasoned 
that CV-3611 plays a key role either in inhibiting 
Harbar-weiss reaction (02-+H2O2-802+OH-+ 
• OH) by inactivation of 02- or in inhibiting 
Fenton reaction (H202+ Fee+-8Fe3++ • OH + OH-) 
by impaired conversion process of Fe3+ to Fe 2+
as a result of blocking of activation pathway") 
of neutrophils with help of a presence of C5a_ 
On the other hand, Halliwell et a125' reported 
that ascorbic aicd biologically scavenges oxidant 
hypochlorous acid by inactivation of a'-anti-
portease. There are few reports regarding 
protection from reperfusion injury on the lung 
although some reports clarify that vitamine E 
(a-TOC) protects brain ischemia26', endotoxic 
damage"), reperfusion injury from renal 
ischemia28' and mycocardial protection 29). It is 
well known that a-TOC is present in the cell 
membrane and inhibits generation of lipid 
peroxidase by reacting with lipid peroxiradical 
and free radical whic is generated in the cell 
membrane","), although it does not almost 
react with 02- generated via xanthin oxidase 
system. Reddanna32) reported that a-TOC inhib-
its 5-lipoxygenase activity and also prohibits 
generation of LT which acts as a strong tis-
sue destruction. From a result of this study, 
it is not certain that a-TOC directly inhibits 
generation of oxidative product from neu-
trophis. The reason for activation of neutro-
phils is that a-TOC neither react with 02- nor 
inhibit C5a production. It is suggested that the 
mechanism causing cell damage by leu-
cocytes should be that activated leucocytes 
adher to the endothelium of the vessel, and on 
the consequence, elastase released from acitvat-
ed leucocytes causes damage to endothelium of 
the vessel, change in matrix beneath the basal 
membrane and progress in destruction of 
alveolar epithelium'). 
 From this study, it was certified that CV-3611 
and a-TOC administrations functionally pro-
duced satisfactory alveolar ventilation, reflect-
ing inhibited generation of lipid peroxidase in 
the lung. In contrast, both drugs could not be 
beneficial in preventing an increase in pul-
monary vascular resistence and extravascular 
lung water. 
 Histologic examination revealed that alveolar 
structure was kept almost satisfactory in drugs 
administration as compared with that in non-
drugs administration. However, the findings of 
perivaschlar edema and bleeding in drugs were 
almost the same as non-drugs administration. 
 It is concluded that CV-3611 and a-TOC are 
not so effctive as to be expected to prevent a
donor lung from causing damage to the 
endothelium of the vessels. In contrast, these 
are of great benefit to prevent a donor lung from 
changes in matrix beneath the basal membrane 
and destruction of alveolar epithelium. 
 Some reprots certified that a-TOC bene-
fits the storage organs from elimination of lipied 
peroxidase generatd by the cell membrane"' 
and it also facilitates antioxidative actions of 
ascorbic acid and a-TOC34'. This study clarifi-
ed that static compliance used as an par-
ameter of lung edema was remained satisfac-
tory and generation of lipid peroxidase in the 
lung was depressed. These results in this series 
were consistent with those which were drawm 
by reports desdribed previously.
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